ACH

Business Context and Reporting Period

Company: Owens & Minor, Inc. (Note: Input metadata referenced "Accendra Health Inc," but the filing text is for Owens & Minor, Inc.)
Reporting Period: Year ended December 31, 2002
Business Overview: Owens & Minor is the leading distributor of national name-brand medical and surgical supplies in the United States. It distributes over 120,000 products from approximately 1,100 suppliers to roughly 4,000 customers, primarily acute-care hospitals and integrated healthcare networks (IHNs). The company operates 41 distribution centers nationwide and offers value-added services including supply chain management consulting (OMSolutions) and third-party logistics.

Key Financial Metrics

Note: All figures in thousands except per share data and percentages.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 4% to $3.96 billion in 2002 compared to 2001. Growth was driven by new business and penetration of existing accounts, partially offset by customer losses in late 2001/early 2002 related to Novation contract renewals.
• Profitability Surge: Net income more than doubled to $47.3 million from $23.0 million in 2001. This improvement was driven by increased sales, reduced financing costs, and better operating expense control.
• Accounting Change (Goodwill): Effective January 1, 2002, the company adopted SFAS 142, eliminating goodwill amortization. Prior year data was restated to exclude this expense for comparability. Reported income before extraordinary items excluding goodwill amortization was $47.2 million in 2002 versus $35.4 million in 2001.
• Unusual Items:
  • 2002: Included a $3.0 million charge (SG&A) for cancelling a mainframe computer services contract and a $50,000 extraordinary gain on repurchasing preferred securities.
  • 2001: Included a $7.2 million tax provision for disallowed interest deductions, a $1.1 million investment impairment, and a $7.1 million extraordinary loss on early debt retirement.
• Financing Costs: Net financing costs decreased to $12.2 million in 2002 from $17.7 million in 2001, due to lower outstanding financing levels and lower interest rates.

Guidance, Outlook, and Risks

• 2003 Outlook: Management anticipates sales growth in the 3% to 6% range. Gross margins are expected to face continued competitive pressure, though the company plans to pursue margin improvements through value-added services and its MediChoice private label line.
• Strategic Initiatives: The company is investing in OMSolutions (consulting/outsourcing) and Third Party Logistics (3PL) services. Increased investment in these areas and in-house training is expected in 2003.
• Liquidity: The company maintains a $150 million revolving credit facility (with $118.1 million unused as of year-end) and a $225 million off-balance sheet receivables financing facility. Management believes available financing is sufficient for working capital and strategic growth.
• Key Risks:
  • Customer Concentration: Sales to Novation members represented approximately 50% of net sales in 2002. Loss of a major customer could significantly impact the business.
  • Competition: The industry is highly competitive with Cardinal Health and McKesson Medical-Surgical. Pricing pressure remains a factor.
  • Legal Proceedings: Approximately 191 lawsuits regarding latex product injuries were pending as of year-end. Management believes the likelihood of material loss is remote due to indemnification agreements and insurance.
  • Interest Rate Risk: The company uses interest rate swaps to manage exposure. A 100 basis point increase in rates could reduce pre-tax earnings by approximately $1.0 million annually.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the Novation contract, which accounts for ~50% of sales.
• Cash Flow Discrepancy: Investigate the negative operating cash flow of $(14.3) million despite positive net income of $47.3 million. This was driven by a $70 million net decrease in receivables sold and a $40 million decrease in accounts payable.
• Goodwill Valuation: Review the annual impairment testing of the $198.1 million goodwill balance under SFAS 142.
• Debt Covenants: Confirm continued compliance with debt covenants regarding leverage ratios and fixed charge coverage, especially given the increase in long-term debt.
• IT Contract Transition: Assess the impact of the new seven-year IT outsourcing agreement with Perot Systems and the associated $3.0 million termination charge from the previous contract.